Cargando…
The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells
Multidrug resistance (MDR) is a major cause of the inefficacy and poor response to paclitaxel-based chemotherapy. The combination of conventional cytotoxic drugs has been a plausible strategy for overcoming paclitaxel resistance. Herein, we investigated the cytotoxic effects and underlying mechanism...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150343/ https://www.ncbi.nlm.nih.gov/pubmed/29072615 http://dx.doi.org/10.3390/molecules22111822 |
_version_ | 1783356972312035328 |
---|---|
author | Ji, Liyan Liu, Xi Zhang, Shuwei Tang, Shunan Yang, Simin Li, Shasha Qi, Xiaoxiao Yu, Siwang Lu, Linlin Meng, Xiangbao Liu, Zhongqiu |
author_facet | Ji, Liyan Liu, Xi Zhang, Shuwei Tang, Shunan Yang, Simin Li, Shasha Qi, Xiaoxiao Yu, Siwang Lu, Linlin Meng, Xiangbao Liu, Zhongqiu |
author_sort | Ji, Liyan |
collection | PubMed |
description | Multidrug resistance (MDR) is a major cause of the inefficacy and poor response to paclitaxel-based chemotherapy. The combination of conventional cytotoxic drugs has been a plausible strategy for overcoming paclitaxel resistance. Herein, we investigated the cytotoxic effects and underlying mechanism of LSS-11, a novel naphthalimide derivative-based topoisomerase inhibitor, in paclitaxel-resistant A549 (A549/T) lung cancer cells. LSS-11 enhanced cell death in A549/T cells by inducing apoptosis through increasing the DR5 protein level and PARP1 cleavage. Importantly, LSS-11 dose-dependently reduced STAT3 phosphorylation and downregulated its target genes MDR1 and MRP1, without affecting P-gp transport function. Chromatin coimmunoprecipitation (ChIP) assay further revealed that LSS-11 hindered the binding of STAT3 to the MDR1 and MRP1 promoters. Additionally, pharmacological inhibition of p-STAT3 by sulforaphane downregulated MDR1 and MRP1, resulting in A549/T cell death by triggering apoptosis. Collectively, our data show that LSS-11 is a potent naphthalimide-based chemosensitizer that could enhance cell death in paclitaxel-resistant lung cancer cells through the DR5/PARP1 pathway and STAT3/MDR1/MRP1 STAT3 inhibition. |
format | Online Article Text |
id | pubmed-6150343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61503432018-11-13 The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells Ji, Liyan Liu, Xi Zhang, Shuwei Tang, Shunan Yang, Simin Li, Shasha Qi, Xiaoxiao Yu, Siwang Lu, Linlin Meng, Xiangbao Liu, Zhongqiu Molecules Article Multidrug resistance (MDR) is a major cause of the inefficacy and poor response to paclitaxel-based chemotherapy. The combination of conventional cytotoxic drugs has been a plausible strategy for overcoming paclitaxel resistance. Herein, we investigated the cytotoxic effects and underlying mechanism of LSS-11, a novel naphthalimide derivative-based topoisomerase inhibitor, in paclitaxel-resistant A549 (A549/T) lung cancer cells. LSS-11 enhanced cell death in A549/T cells by inducing apoptosis through increasing the DR5 protein level and PARP1 cleavage. Importantly, LSS-11 dose-dependently reduced STAT3 phosphorylation and downregulated its target genes MDR1 and MRP1, without affecting P-gp transport function. Chromatin coimmunoprecipitation (ChIP) assay further revealed that LSS-11 hindered the binding of STAT3 to the MDR1 and MRP1 promoters. Additionally, pharmacological inhibition of p-STAT3 by sulforaphane downregulated MDR1 and MRP1, resulting in A549/T cell death by triggering apoptosis. Collectively, our data show that LSS-11 is a potent naphthalimide-based chemosensitizer that could enhance cell death in paclitaxel-resistant lung cancer cells through the DR5/PARP1 pathway and STAT3/MDR1/MRP1 STAT3 inhibition. MDPI 2017-10-26 /pmc/articles/PMC6150343/ /pubmed/29072615 http://dx.doi.org/10.3390/molecules22111822 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ji, Liyan Liu, Xi Zhang, Shuwei Tang, Shunan Yang, Simin Li, Shasha Qi, Xiaoxiao Yu, Siwang Lu, Linlin Meng, Xiangbao Liu, Zhongqiu The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells |
title | The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells |
title_full | The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells |
title_fullStr | The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells |
title_full_unstemmed | The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells |
title_short | The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells |
title_sort | novel triazolonaphthalimide derivative lss-11 synergizes the anti-proliferative effect of paclitaxel via stat3-dependent mdr1 and mrp1 downregulation in chemoresistant lung cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150343/ https://www.ncbi.nlm.nih.gov/pubmed/29072615 http://dx.doi.org/10.3390/molecules22111822 |
work_keys_str_mv | AT jiliyan thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT liuxi thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT zhangshuwei thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT tangshunan thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT yangsimin thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT lishasha thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT qixiaoxiao thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT yusiwang thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT lulinlin thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT mengxiangbao thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT liuzhongqiu thenoveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT jiliyan noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT liuxi noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT zhangshuwei noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT tangshunan noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT yangsimin noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT lishasha noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT qixiaoxiao noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT yusiwang noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT lulinlin noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT mengxiangbao noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells AT liuzhongqiu noveltriazolonaphthalimidederivativelss11synergizestheantiproliferativeeffectofpaclitaxelviastat3dependentmdr1andmrp1downregulationinchemoresistantlungcancercells |